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Abstract
Background: Cell proliferation control depends in part on the carefully ordered regulation of
transcription factors. The p53 homolog p73, contributes to this control by directly upregulating the
cyclin dependent kinase inhibitor, p21waf1/cip1. E2F1, an inducer of cell proliferation, directly
upregulates p73 and in some systems upregulates p21 directly. Because of its central role in
controlling cell proliferation, upregulation of p21 has been explored as a modality for treating
bronchogenic carcinoma (BC). Improved understanding of p21 transcriptional regulation will
facilitate identification of BC tissues that are responsive to p21-directed therapies. Toward this
goal, we investigated the role that E2F1 and p73 each play in the transcriptional regulation of p21.
Results: Among BC samples (N = 21) p21 transcript abundance (TA) levels varied over two
orders of magnitude with values ranging from 400 to 120,000 (in units of molecules/106 molecules
β-actin). The p21 values in many BC were high compared to those observed in normal bronchial
epithelial cells (BEC) (N = 18). Among all BC samples, there was no correlation between E2F1 and
p21 TA but there was positive correlation between E2F1 and p73α (p < 0.001) TA. Among BC cell
lines with inactivated p53 and wild type p73 (N = 7) there was positive correlation between p73α
and p21 TA (p < 0.05). Additionally, in a BC cell line in which both p53 and p73 were inactivated
(H1155), E2F1 TA level was high (50,000), but p21 TA level was low (470). Transiently expressed
exogenous p73α in the BC cell line Calu-1, was associated with a significant (p < 0.05) 90% increase
in p21 TA and a 20% reduction in E2F1 TA. siRNA mediated reduction of p73 TA in the N417 BC
cell line was associated with a significant reduction in p21 TA level (p < 0.01).
Conclusion: p21 TA levels vary considerably among BC patients which may be attributable to 1)
genetic alterations in Rb and p53 and 2) variation in TA levels of upstream transcription factors
E2F1 and p73. Here we provide evidence that p73 upregulates p21 TA in BC tissues and
upregulated p21 TA may result from E2F1 upregulation of p73 but not from E2F1 directly.
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Cell cycle homeostasis in normal human bronchial epi-
thelial cells (BEC) is highly regulated at the G1/S transi-
tion. In G1 phase of the cell cycle, formation of a
heterodimeric complex between cyclin D and cyclin
dependent kinases 4 or 6 (cdk 4,6) leads to the phospho-
rylation of the tumor suppressor retinoblastoma gene
product (pRb) [1-3]. Phosphorylation causes conforma-
tional change of the pRb/E2F complex, followed by
release, and activation of the E2F1, 2, and 3 transcription
factors [4-6]. Free E2F proteins bind strongly to DNA and
were first identified by their ability to transactivate the
adenoviral E2 promoter [7]. E2F1 functions to upregulate
transcription of genes required for entry into S phase,
including cyclin E, c-myc and itself [8-10]. In turn, c-myc
directly upregulates transcription of cyclin E and cdk4
[11,12]. Thus, phosphorylation of pRb by one or more
cyclin/cdk complexes causes activation and upregulation
of E2F1, upregulation of c-myc transcription by E2F1, and
upregulation of cdk4 transcription by c-myc. These inter-
actions are initiated at the restriction point of G1/S, which
is associated with independence of the cell from extracel-
lular growth factors [4,13]. The events described above
contribute to a cell proliferation signal amplification cycle
that would be uncontrolled in the absence of compensa-
tory negative feedback.
Compensatory feedback signals, including the activation
of p53 and transcriptional upregulation of p73 and
p21waf1/cip1 (p21 hereafter) act to slow cell proliferation
[14-16]. Unlike p53, p73 is not frequently mutated in
human cancers [17], and thus it is not considered a classi-
cal tumor suppressor gene, as defined by Knudson's two
hit hypothesis [18,19]. However, it functions to promote
cell cycle arrest, DNA repair, and apoptosis much like p53
[18,20]. E2F1 (and c-myc) transactivation of p14ARF leads
to stabilization of p53 [21,22] which slows cell cycling
through the upregulation of p21 [23,24], and also induces
apoptosis [25]. E2F1 also upregulates p73 [15,26,27] and
p73 upregulates p21 [15], which in turn acts to inhibit the
release of E2F1 from pRb, resulting in compensatory feed-
back for the loss of cell proliferation control. In some sys-
tems, E2F1 also upregulates p21 directly [28].
In previous studies, we determined that p21 transcript
abundance (TA) levels vary considerably among broncho-
genic carcinoma (BC) primary tissues and cell lines, and
in some of these samples the p21 TA level is higher than
the level observed in normal BEC [29,30]. Because p21
normally slows cell proliferation, this observation was
unexpected, and counter-intuitive. If validated, these pre-
liminary findings would have important implications for
the many efforts presently underway to design gene spe-
cific cancer treatments that function to achieve cell prolif-
eration control [31].
The purpose of this study was to better understand inter-
tumor variation in the mechanisms responsible for loss of
proliferation control and to better define the role of E2F1,
p73 and p21 regulatory pathways as they relate to cell pro-
liferation control in human BC. Our approach included
additional descriptive studies in BC cell lines, as well as
primary BC tissues and normal BEC to better quantify
inter-tumor variation of p21 TA levels. With respect to the
fourteen BC cell lines used in this study, because each has
been extensively characterized at the genetic level
[17,25,32-35], we were better able to define the regulatory
relationship between E2F1, p73, and p21 after consider-
ing the known alterations in each individual cell line. Our
descriptive approach was followed by experimental test-
ing of the hypothesis posed to explain these observations.
Results
Transcript abundance (TA) levels of E2F1, p73α, and p21
in normal bronchial epithelial cells (BEC) (N = 18) and
bronchogenic carcinoma (BC) tissues (N = 21) were meas-
ured by StaRT-PCR. Cultured cells and primary tissues are
shown in Tables 1 and 2, respectively. For the BC cell
lines, known alterations in p53, p16, p14ARF, Rb, p73, and
c-myc also are presented, along with the TA values. Bivari-
ate analysis of the TA data from these cultured human
BEC samples provided data consistent with observations
in other tissues that E2F1 regulates p73 transcription
[15,26,27] and that p73 regulates p21 transcription [15].
However, in contrast to other cell types, they suggested
that E2F1 does not directly regulate p21 transcription. To
further investigate the significance of this finding, seven
primary BC tissues (Table 2) were also assessed.
The mean, median, and quartile values for each gene in
normal (N = 18) compared to malignant samples (N =
21) are shown in Table 3. E2F1 TA levels were over 30-fold
higher in BC relative to normal BEC (p < 0.0001). Con-
versely, mean p73α TA was higher in normal BEC by over
2-fold, but this difference was not statistically significant
(p = 0.07), although the median p73 TA value was higher
in normal BEC by nearly 9-fold. With respect to p21 TA
level, there was no statistical difference in the mean value
between the two groups.
Median and quartile values were used to determine if TA
levels were high or low for a given sample. For example,
the median value for E2F1 in BC was 19,000. Therefore, a
sample with an E2F1 TA level greater than 19,000 would
be considered high and a TA level less than 19,000 would
be considered low. These criteria were used to identify cell
lines with low (Calu-1) or high (N417) p73α TA for use
in the exogenous p73 and p73 siRNA transfection
experiments.Page 2 of 10
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Molecular Cancer 2005, 4:23 http://www.molecular-cancer.com/content/4/1/23Table 1: Transcript abundance measurements for cultured normal BEC and BC cell lines
Sample Cell Type Medium Genetic Alterations Transcript Abundance
p53 p16 p14ARF Rb p73 c-myc E2F1 p73α p21
17378B N B 1,500 1 21,000
6F0333B N B 4,700 1 76,000
6F0395B N B 5,100 1 120,000
SW900 Sq R I 7,300 100 12,000
Calu-1 Sq R I I 8,500 28 2,000
H460 LC R I 9,000 14 18,000
H82 SC R I I I A 15,000 17 400
A549 A R I I 16,000 1 6,200
A2126 A R I 17,000 30 6,100
N417 SC R I I A 19,000 5,200 34,000
H322 BA R I I 20,000 190 31,000
H446 SC R I A 67,000 710 120,000
H1155* LC R I I I 50,000 250 470
H520 Sq R I I 56,000 120 2,300
H146 SC R I 59,000 700 19,000
H661 LC R I I 76,000 210 58,000
A427** A R I 180,000 220 100,000
N, normal; Sq, squamous carcinoma; LC, large cell carcinoma; SC, small cell carcinoma; A, adenocarcinoma; BA, bronchoalveolar carcinoma; B, 
BEGM medium; R, RPMI with 10% FBS; I, inactivated; A, amplification. Non-detectable TA were entered as 1 to allow plotting on a logarithmic scale. 
Cell lines are grouped by increasing E2F1 TA. All values are in units of molecules/106 molecules β-actin and represent the mean from three 
independent measurements. *H1155 has a missense mutation in the transactivation domain of p73. **A427 has a deletion in the p73 coding 
sequence but the protein product still retains its transactivational function [35].
Table 2: Transcript abundance measurements for primary normal BEC and BC tissues
Sample ID Diagnosis Cell Type E2F1 p73α p21
63 NC N 270 850 14,000
282 NC N 540 640 10,000
64 NC N 2,000 400 10,000
285 NC N 2,500 870 3,100
257 NC N 270 5,200 12,000
156 NC N 750 1,000 25,000
194 NC N 290 3,800 3,500
150 NC N 160 3,700 11,000
136 NC N 700 31 9,100
261 NC N 250 3,100 30,000
191 C N 150 900 13,000
158 C N 190 2,200 11,000
146 C N 230 2,600 9,100
34 C N 570 4,400 12,000
212 C N 600 5,300 35,000
274 C Sq 730 1 7,000
279 C A 1,200 1 4,000
190 C BA 6,600 3 27,000
102 C A 12,000 21 21,000
165 C SC 36,000 4,300 16,000
123 C Sq 54,000 5,500* 90,000
277* C A 120,000 100 2,000
NC, non-cancer; C, cancer; N, normal; Sq, squamous carcinoma; A, adenocarcinoma; BA, bronchoalveolar carcinoma; SC, small cell carcinoma. 
Non-detectable TA were entered as 1 to allow plotting on a logarithmic scale. Normal BEC are grouped by diagnosis and cell type. BC tissues are 
grouped by increasing E2F1 TA. All values are in units of molecules/106 molecules β-actin and represent the mean from three independent 
measurements. *This value represents the mean from two measurements due to insufficient sample.Page 3 of 10
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Molecular Cancer 2005, 4:23 http://www.molecular-cancer.com/content/4/1/23Table 3: Descriptive statistics for E2F1, p73α, and p21 transcript abundance measurements
Normal BEC Bronchogenic Carcinoma
E2F1 p73α p21 E2F1 p73α p21
Mean 1,200 1,900 24,000 Mean 40,000 840 25,000
Min 150 1 3,100 Min 730 1 400
LQ 260 460 10,000 LQ 9,000 17 4,000
Median 560 950 12,000 Median 19,000 100 12,000
UQ 1,300 3,600 24,000 UQ 56,000 250 27,000
Max 5,100 5,300 120,000 Max 180,000 5,500 120,000
Min, minimum; LQ, lower quartile; UQ, upper quartile; max, maximum. Values were derived from statistical analysis of samples presented in Tables 
1 and 2.
Lack of correlation between E2F1 and p21 TAFigure 1
Lack of correlation between E2F1 and p21 TA. There was no correlation between E2F1 and p21 TA among BC cell lines 
(N = 14) and primary BC tissues (N = 7). Each point represents the mean value from triplicate measurements of E2F1 and p21 
as shown in Tables 1 and 2 (except where indicated).
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Molecular Cancer 2005, 4:23 http://www.molecular-cancer.com/content/4/1/23Bivariate analysis of E2F1 and p21
There was no significant correlation between E2F1 and
p21 TA levels among BC cell lines and primary tissues (N
= 21) (Figure 1).
Bivariate analysis of E2F1 and p73α TA levels
E2F1 and p73α TA values were positively correlated (p <
0.001) among BC cell lines and primary tissues (N = 21)
(Figure 2).
Bivariate analysis of p73α and p21 TA levels
Among BC cell lines in which p53 is known to be com-
pletely inactivated by mutation or deletion (N = 7), p73α
and p21 were significantly correlated (p < 0.05), as shown
in Figure 3. In contrast, there was a borderline but insig-
nificant (p = 0.06) positive correlation between p73α and
p21 TA among all BC cell lines and primary tissues (N =
21). This result may be explained by p53 regulation of
p21 transcription as a confounding variable in those cell
lines with wild type p53.
E2F1 and p21 TA analysis in BC cell line with inactivated 
p53 and p73
In the H1155 cell line in which p53 and p73 are both
inactivated, E2F1 TA level was high, yet p21 TA level was
low (Table 1). Consistent with our observation that E2F1
and p73α are correlated in BC tissues (Figure 2), E2F1 and
p73α TA levels were both high in H1155. However, the
missense mutation in the DNA binding domain of p73
inhibits its transactivational function [35]. Thus, H1155 is
a cell line with a naturally occurring p73 mutation that
directly supports our hypothesis that p21 is not upregu-
lated by E2F1 directly.
Bivariate analysis of E2F1 and p73α TAF gure 2
Bivariate analysis of E2F1 and p73α TA. E2F1 and p73α TA were positively correlated among BC cell lines (N = 14) and 
primary BC tissues (N = 7). Each point represents the mean value from triplicate measurements of E2F1 and p73α as shown in 
Tables 1 and 2 (except where indicated).
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p21 and decreased E2F1 TA in Calu-1
To test the hypothesis that p21 transcription is regulated
by p73 and not by E2F1 directly, p73α was transiently
expressed in the squamous carcinoma cell line Calu-1.
This line expresses low levels of endogenous p73α TA
(28), low levels of p21 TA (2,000), and low levels of E2F1
TA (8,500). p73α TA was induced over 1,000-fold relative
to the mock, 24 hours post-transfection (Figure 4A). Exog-
enous p73 protein expression was confirmed by Western
analysis using an anti-HA antibody specific for an amino
terminal tag on p73 (Figure 4B). p21 and E2F1 TA levels
were quantified 24 hours post-transfection. While p21 TA
was upregulated 90% (p < 0.001) relative to mock-trans-
fected cells, there was a 20% downregulation (p < 0.05) of
E2F1 TA (Figure 4C).
Gene specific silencing of p73 associated with decreased 
p21 TA level
According to bivariate analysis shown in Figure 3, p73α
and p21 were significantly correlated in cell lines that
have inactivated p53. Therefore, we anticipated that gene
specific silencing of p73 in one of these lines would
directly reduce p21 TA. We used a pool of siRNAs to target
all isoforms of p73 in the null-p53 small cell carcinoma
N417. This cell line is an appropriate model because it
expresses high p21 (34,000), E2F1 (19,000), and endog-
enous p73α (5,200) TA levels. p73α TA decreased by 80%
Bivariate analysis of p73α and p21 TAF gure 3
Bivariate analysis of p73α and p21 TA. p73α and p21 TA were positively correlated (p < 0.05) among BC cell lines (N = 
7) where p53 was known to be inactivated by mutation or deletion and p73 was wild type. Each point represents the mean 
value from triplicate measurements of p73α and p21 as shown in Table 1.
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Molecular Cancer 2005, 4:23 http://www.molecular-cancer.com/content/4/1/23relative to the non-specific siRNA control (p < 0.05),
while p21 TA decreased by 70% (p < 0.01).
Discussion
Relative to normal bronchial epithelial cells (BEC), p21 is
upregulated in some bronchogenic carcinoma (BC) tis-
sues and downregulated in others (Tables 1, 2, and 3). Ele-
vation of p21 TA in malignant cells may seem counter-
intuitive because it would be expected to slow cell prolif-
eration. However, in some tumors pRb is dysfunctional
and feedback signals such as p73 upregulation by E2F1
may increase p21 transcription in an ineffective attempt to
prevent phosphorylation of pRb and release of activated
E2F1. It is likely that such tumors would be poor candi-
dates for therapy intended to control cell proliferation
through specific upregulation of p21 transcription.
However, in other tumors, such as those with a genetic
profile similar to that of A549 or Calu-1 (Table 1), pRb is
intact, and TA levels of E2F1, p73, and p21 are all low. In
a tumor such as this, there is reason to believe that the
upregulation of p21 transcription would be an effective
treatment. However, in order to develop effective p21
gene-specific therapeutics, and biomarkers that predict
which tumor will respond, it is necessary to better under-
stand p21 transcriptional regulation.
In some cell types, E2F1 directly regulates p21 [28], how-
ever, the data presented here support the hypothesis that
E2F1 does not upregulate p21 directly in human BC, but
rather, elevated p21 TA results from E2F1 upregulation of
p73. This hypothesis, generated initially from empirical
observation, is supported by experimental data. There
were four supportive empirical observations. First, there
was lack of correlation between E2F1 and p21 TA among
BC tissues. Second, there was positive correlation among
BC tissues between E2F1 and p73 TA. Third, there was
positive correlation between p73 and p21 TA among BC
cell lines with inactivated p53. Fourth, in the H1155 BC
cell line, in which p53 and p73 are inactivated, E2F1 and
p73 TA levels were high, but p21 TA level was low. If E2F1
upregulated p21 directly, it would be reasonable to expect
that p21 would be upregulated in this cell line, not
downregulated.
In experiments designed to directly test this hypothesis,
transient exogenous expression of p73α was associated
with increased p21 and decreased E2F1 TA levels and
siRNA mediated silencing of p73 was associated with
decreased p21 TA levels. Although the siRNA experiments
support our hypothesis, they are not as supportive as the
transient transfection experiments because E2F1 TA was
reduced along with p73 and p21. We speculate that this
decrease was due to a non-specific effect of the siRNAs. A
non-specific effect of the siRNA method has been
Effect of p73α transient expression on p73α, p21, and E2F1 TA in Calu-1 cellsFigure 4
Effect of p73α transient expression on p73α, p21, and 
E2F1 TA in Calu-1 cells. A) p73α TA was induced by 
over 3 orders of magnitude relative to mock transfected 
cells. Calu-1 cells were transfected with 5 µg of GFP control 
plasmid or HA-p73α. B) Total HA-p73 protein was analyzed 
in mock or p73α transfected cells. 20 µg of lysate were blot-
ted on a PDVF membrane and incubated with an anti-hemag-
glutinin primary antibody conjugated to HRP. C) p21 was 
upregulated by 90% and E2F1 was reduced by 20% in p73α 
transfected cells. Results represent the mean value from trip-
licate measurements from three independent experiments. 
Error bars represent the S.E.M. RNA was extracted 24 hours 
post-transfection and treated with DNaseI. RNA was PCR 
amplified to rule out the possibility of plasmid contamination. 
No PCR products were detected.
Mock p73 
HA-p73
A
B
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and p21 [36].
Conclusion
In this study, we provide strong empirical and experimen-
tal evidence that in human bronchogenic carcinoma, p21
transcription is regulated by p73 but, in contrast to other
cell types, not directly by E2F1. This knowledge will facil-
itate a) development of p21 gene-specific therapeutics
necessary for individualized treatment strategies, and b)
discovery of biomarkers that will predict which tumors
will respond to p21 gene-specific therapeutics.
Methods
Normal cell populations
Normal BEC stock populations (lot numbers: 17378,
6F0333, 6F0395) were obtained from Clonetics (San
Diego, CA) and incubated in BEGM medium.
Carcinoma cell lines
Fourteen BC cell lines (Table 1) were obtained from
American Type Culture Collection (Rockville, MD) and
incubated in RPMI with 10% FBS.
Culture conditions
Normal BEC and BC cells proliferate optimally under dif-
ferent conditions [37]. The medium that is optimal for BC
cell lines, RPMI with 10% fetal bovine serum (FBS),
induces terminal squamous differentiation in normal
BEC [38]. In contrast, BC cell lines do not divide in serum-
free media that are optimal for proliferation of normal
BEC. BC cell lines were incubated in RPMI with 10% FBS
and normal BEC from three individuals were incubated in
bronchial epithelial growth medium (BEGM). In order to
directly compare with carcinoma cell lines under the same
optimal conditions, normal BEC cell populations (17378,
6F0333, 6F0395) were also incubated for 24 hours in
RPMI with 10% FBS.
Primary tissue samples
Primary normal BEC and primary BC samples (Table 2)
were obtained under IRB approved protocols as previ-
ously described [29,39,40]. In each case informed consent
was obtained from the patient.
RNA extraction and reverse transcription
Total RNA was extracted by phenol/chloroform methods
using TRI-Reagent (Molecular Research Center, Inc.,
Cincinnati, OH). Approximately 1 µg of total RNA was
reverse transcribed using oligo dTs and MMLV-reverse
transcriptase (Invitrogen, Inc., Carlsbad, CA).
Transcript abundance measurement
Transcript abundance (TA) was measured by Standardized
RT (StaRT)-PCR [30,41,42]. With this method there is an
internal standard, within a standardized mixture of inter-
nal standards (SMIS) for each gene amplified in the PCR
reaction. This enables regular assessment of performance
characteristics as recommended by recent FDA guidelines
[43]. Among these performance characteristics are repro-
ducibility, lower detection threshold, linear dynamic
range, signal to analyte response, false negatives, and false
positives. For each gene measured in this study, the lower
detection threshold was less than 10 molecules and the
linear dynamic range was less than 10 to greater than 107
molecules. False negatives are eliminated due to the pres-
ence of an internal standard and false positives are
eliminated by using a water control to ensure that there is
no contamination within the PCR reaction.
The reagents for analysis of E2F1 and p21 were commer-
cially prepared (Gene Express, Inc., Toledo, OH). To ana-
lyze p73, a SMIS containing internal standards for only
p73 and β-actin were prepared in this laboratory, because
p73 is not in a commercially available SMIS. p73 forward
and reverse primers amplify at least four distinct isoforms
including α-δ, but do not distinguish between the full-
length and ∆N transcripts. A separate pair of primers pub-
lished by Kartasheva, et al. [44] were used to determine
the presence of ∆Np73. The internal standard for p73 was
prepared using the forward primer and a competitive tem-
plate (CT) primer. The CT primer hybridizes upstream of
the reverse primer but retains its sequence at the 5' end
[45]. This enables the simultaneous amplification of the
internal standard and endogenous native template (NT)
using only the forward and reverse primers. p73 forward
and reverse primer sequences are as follows: p73 F, 5' ACT
TTG AGA TCC TGA TGA AG 3' R, 5' CAG ATG GTC ATG
CGG TAG TG 3'. Primer sequences for p21 and E2F1 were
previously reported [30].
Six SMISs (A-F) were used for all TA measurements, with
p73 CT at concentrations ranging from 10-12 (SMIS A) to
10-17 M (SMIS F) and β-actin CT constant at 10-13 M in all
six SMISs. The dilution of each cDNA sample that con-
tained 60,000 molecules of β-actin cDNA was determined
through calibration to 1 µL of SMIS F. Such calibrated
samples were then used in all StaRT-PCR experiments. In
some experiments, if the amount of cDNA sample
available was low, the cDNA and the SMIS were both
diluted 10-fold. Equal volumes of cDNA and SMIS were
combined in a master mix along with 30 mM MgCl2
(Idaho Technology, Inc., Idaho Falls, ID), 2 mM dNTPs,
Taq Polymerase (Promega, Madison, WI), and RNase-free
water. For each TA measurement, a 10 µL reaction volume
was PCR amplified in a Rapidcycler (Idaho Technology,
Inc., Idaho Falls, ID) for 35 cycles. PCR reactions were
denatured for 5 seconds at 94°C, annealed for 10 seconds
at 58°C, and elongated for 15 seconds at 72°C.Page 8 of 10
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A pcDNA 3.0 (Invitrogen Inc., Carlsbad, CA) expression
vector was kindly provided from the laboratory of Vin-
cenzo DeLaurenzi (University of Rome, Italy). The p73
gene contains a hemagglutinin tag sequence and is regu-
lated by a CMV promoter sequence. An expression vector
encoding a CMV regulated green fluorescent protein was
obtained from (Gene Therapy Systems, San Diego, CA),
and used as a negative control (mock) and determinant
for transfection efficiency.
Transient transfection assays
Calu-1 cells were incubated in RPMI supplemented with
10% FBS and grown to confluence. Twenty-four hours
prior to transfection, cells were trypsinized and transferred
to 60 mm dishes. For transfections, 5 µg of plasmid DNA
was diluted in 0.5 mL of serum-free medium with the
appropriate concentration of Lipofectamine 2000 trans-
fection reagent (Invitrogen, Inc., Carlsbad, CA). Cells were
incubated with DNA-lipid complexes in serum-contain-
ing medium for 4–8 hours and subsequently treated with
fresh medium. RNA was isolated 24 hours post-transfec-
tion and analyzed by StaRT-PCR. 60 molecules of p73
internal standard were sufficient to quantify endogenous
p73α TA and 6,000 molecules were required to quantify
the combined endogenous and exogenous transcript. To
exclude the possibility that the high level measured was
partly due to amplification of contaminating plasmid
DNA, RNA from p73α transfected Calu-1 cells was PCR-
amplified with p73 specific primers. No PCR product was
observed.
Western blot analysis
Calu-1 cells were lysed 24 hours post-transfection by three
consecutive freeze-thaws in a 0.25 M Tris lysis buffer (Inv-
itrogen, Inc., Carlsbad, CA). Total protein concentration
was determined colorimetrically using the bicinchoninic
acid (BCA) assay (Pierce, Inc., Rockford, IL). 20 µg of total
protein from Calu-1 cells were loaded on a 7% SDS Tris
Acetate NuPage gel (Invitrogen, Inc., Carlsbad, CA). Pro-
teins were transferred to a PVDF membrane and incu-
bated with an anti-HA primary antibody conjugated to
horseradish peroxidase (Santa Cruz Biotechnology, Santa
Cruz, CA). The PVDF was then incubated with
chemiluminescent substrates (Santa Cruz Biotechnology,
Santa Cruz, CA) and visualized by autoradiography.
siRNA (RNAi)
Approximately 1 million N417 cells were incubated in a
six-well plate with RPMI supplemented with 10% FBS.
Five siRNA oligonucleotides specific for the p73 gene or a
non-specific pooled duplex control (Dharmacon, Inc.,
Lafayette, CO) were diluted in serum-free media and
added to the appropriate concentration of TKO transfec-
tion reagent (Mirus Corp., Madison, WI). Untransfected
cells were treated with transfection reagent but not siRNA.
Transfected cells were incubated continuously with siRNA
complexes at a final concentration of 100 nM. RNA was
isolated 24 to 48 hours post-transfection and analyzed by
StaRT-PCR.
Bivariate and statistical analysis
Pearson correlation and paired-sample and independent
T-tests were performed using SPSS 11.5.1 for Windows
(SPSS, Chicago, IL) Due to inter-sample variation it was
necessary to normalize the data by logarithmic
transformation. For each test, a p-value of less than 0.05
was considered statistically significant. Bivariate graphs
were created using Microsoft Excel 2000 (Microsoft Corp,
Redmond, WA).
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